AirAvant Medical Introduces Bongo®Rx A Treatment device for Mild to Moderate Obstructive Sleep Apnea
By: PR-BS Inc.
Deerfield Beach, Fla. – April 23, 2019– AirAvant Medicalis proud to announce that its flagship product, the Bongo®Rx, has received its FDA 510(k) Clearance for the treatment of mild to moderate obstructive sleep apnea (OSA).
Years of painstaking research, development, and testing have yielded a device that is small, portable, and best of all requires no CPAP machine, CPAP hoses, bulky headgear or electricity/
After extensive clinical testing, it was demonstrated the Bongo®Rx significantly reduced the Apnea Hypopnea Index or AHI levels, which is the measurement for the number of apneas and hypopneas recorded per an hour of sleep. AirAvant Medical developed the Bongo®Rx to be convenient and transportable. Its small size allows the user to carry it in a shirt pocket or purse, so the device can be used anywhere at any time.
"We recognize that people need to have the ability to treat their sleep apnea comfortably and conveniently, no matter where they are – in a bed, on a train, on a plane, or even catching a quick nap in a chair or on the couch," said Javier Collazo, Vice-President. "For compliant CPAP patients, the Bongo®Rx may provide a supplemental treatment option to complement their lifestyle. For non-compliant CPAP patients, the Bongo®Rx may provide a patient-friendly, non-cumbersome treatment option to get them refocused and reengaged on treating their obstructive sleep apnea.
About AirAvant, Inc. Medical:
AirAvant Medical (www.airavant.com)
EMI Group, Inc.